Objective. To evaluate whether serum levels of the soluble form of CD30 (sCD30) correlate with disease activity in early rheumatoid arthritis (RA) and may have prognostic value in predicting the response to disease-modifying anti-rheumatic drugs (DMARDs).
T-helper-1 ( Th1)/T-helper-2 (Th2) cell balance could the disease is predictive of a good response to DMARDs. play a key role in modulating the development and In this study, however, they did not find a correlation persistence of chronic inflammation in the joint [1] .
between the Th1/Th2 ratio and disease activity scores There is evidence that a Th1 polyclonal activation or C-reactive protein (CRP). Th1/Th2 balance is not prevails in rheumatoid arthritis (RA) [2] , although it is easy to analyse due to the lack of reliable markers able thought that Th2 cells may produce cytokines in an to distinguish T-cell subsets with distinct cytokine secreattempt to downmodulate inflammation [1] . The idea tion patterns at the site of inflammation. In van der that the natural course of arthritis is modulated by Graaff 's study, for example, the analysis of the Th1/Th2 cytokine balance is appealing, but whether diseaseratio was performed by intracellular staining for either modifying anti-rheumatic drugs (DMARDs) may interinterleukin-4 ( IL-4) or interferon gamma ( IFN-c) in fere with Th1/Th2 cell balance in RA synovitis is still a peripheral blood T cells, which do not strictly reflect the matter of debate [1, 3, 4] . In this setting, it is of interest phenotype and function of T cells found in the joint. In that the recent finding by van der Graaff et al. [5] addition, this methodology is unable to distinguish showed that a low Th1/Th2 ratio at the beginning of unpolarized Th0 cells, i. Basal sCD30 values in patients were much higher than in controls (median 138 U/ml, range 76-415 vs 17 U/ml, through the activation of a subset of T cells with downregulatory activity.
1-96; P < 0.001). Interestingly, we found a strict inverse correlation between sCD30 and CRP serum levels (r = − 0.62, P < 0.005) at baseline, but not during the Materials and methods follow-up. As shown in Table 1 , eight patients responded to therapy at the end of the follow-up. This patient Serum sCD30 levels were evaluated by a commercially available ELISA kit ( Ki-1 antigen ELISA, Dako A/S, subset had sCD30 values at baseline that were notably higher than those of the six patients who did not respond Glostrup, Denmark) and were correlated with CRP levels, measured by laser nephelometry, in 14 Caucasian to therapy (Fig. 1) . It is noteworthy that no demographic differences were present between responders and subjects (11 female, age range 23-62 yr), belonging to the same geographical area (centre regions of Italy), non-responders (data not shown). who fulfilled the 1987 American College of Rheumatology (ACR) diagnostic criteria for RA [13] .
Discussion
Twenty age-and sex-matched healthy volunteers from the same geographical area (16 female, age range
The results of this study demonstrated that sCD30 and CRP serum levels are inversely correlated in early RA 21-61 yr), acted as normal controls. All patients were rheumatoid factor positive and had active disease, as defined by the presence of six or more tender joints, morning stiffness lasting for >45 min or Westergren erythrocyte sedimentation rate (ESR) of ≥ 28 mm/1st h. Patients were studied at the time of diagnosis, early in the course of their disease (<6 months) and, in order to avoid possible pharmacological interference on the immunological data, immediately before starting a DMARD (hydroxychloroquine 400 mg/day). Serum sCD30 and CRP levels were then evaluated every 2 months after the beginning of the treatment. In addition, at baseline and at the end of the follow-up (8 months), ESR and disease activity were evaluated. Disease activity was assessed according to the number of tender and swollen joints, patient's perception of pain measured using a 100 mm visual analogue scale, and patient's and physician's global assessment of disease activity measured with the same scale as above. The response to DMARD therapy, in individual patients, was determined according to the 1985 ACR definition 
